Arenaviral immunotherapies company Hookipa Pharma (Nasdaq: HOOK) has entered into a clinical collaboration and supply agreement with US pharma giant Merck & Co (NYSE: MRK)).
The companies will combine HB-200, Hookipa’s arenaviral immunotherapeutic, and Merck’s big-selling anti-PD-1 therapy, Keytruda (pembrolizumab) as first-line treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC).
Shares in Hookipa were 3% higher during pre-market trading on Wednesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze